Janus Henderson Group PLC Cytom X Therapeutics, Inc. Call Options Transaction History
Janus Henderson Group PLC
- $182 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CTMX
# of Institutions
73Shares Held
50.5MCall Options Held
22.3KPut Options Held
22.9K-
Tang Capital Management LLC San Diego, CA7.79MShares$8.49 Million1.16% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$5.7 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$5.33 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3MShares$3.27 Million0.01% of portfolio
-
Acadian Asset Management LLC Boston, MA2.73MShares$2.97 Million0.01% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $71.9M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...